Recently, BIOKANGTAI’s wholly-owned subsidiary, Beijing Minhai Biotechnology, has signed a sales contract with its Indonesian partner, in which a detailed agreement was made on the quantity, unit price, total amount of the order, and shipment date of the world’s first dual-carrier 13-valent pneumococcal conjugate vaccine developed and produced by BIOKANGTAI to be exported to Indonesia. In October 2023, Minhai Biotech obtained the Marketing License for 13-valent Pneumococcal Polysaccharide Conjugate Vaccine issued by the Indonesian Food and Drug Administration, marking that the vaccine has the basic conditions for sale in the local market in Indonesia. The signing of this contract indicates that after years of market expansion, Kangtai’s 13-valent pneumococcal vaccine has formally opened for overseas sales, and as the relevant work continues to progress, this variety will bring new growth points for the company’s 2024 annual results. Dr. Lucia Rizka Andalusia, Acting Head of Indonesia’s Food and Drug Regulatory Agency ...
Shenzhen Biokangtai Pharmaceutical Co., Ltd. (hereinafter referred to as “BIOKANGTAI”), a wholly-owned subsidiary of BIOKANGTAI (hereinafter referred to as “the Company”), has recently received a notification of acceptance from the State Drug Administration, agreeing to accept the application for clinical trial of 20-valent Pneumococcal Sugar Conjugate Vaccine (hereinafter referred to as “20-valent Pneumococcal Conjugate Vaccine”) developed by BIOKANGTAI. (hereinafter referred to as “Minhai Biotechnology”), a wholly-owned subsidiary of the Company, has recently received a notification of acceptance issued by the State Drug Administration, agreeing to accept the application for clinical trial of the 20-valent Pneumococcal Polysaccharide Conjugate Vaccine developed by Minhai Biotechnology: I. Main contents of the acceptance notice Product Name: 20-valent pneumococcal polysaccharide conjugate vaccine Application: domestic production of drugs registered for clinical trials Applicant: Beijing Minhai Biotechnology Co. Ltd. Acceptance No.: CXSL2400053 According to the “People’s Republic of China Administrative License Law”, Article 32 of the provisions of ...
2023 was riddled with labor strikes across industries as workers lobbied for higher pay amid economic headwinds that shook up the global economy. As for the biopharma industry, employees are more content with their income compared with workers in other fields, a new report suggests. USA Today recently analyzed more than 3 million reviews on the employee review service Glassdoor, focusing on 500 large companies in 25 industries and seeking to identify the industries with the highest number of pay-related complaints. Employees in the pharma and biotechnology sector reported the fewest number of pay complaints, according to the report. On the flip side, the healthcare field took the second-highest position for pay frustration, second only to education. Some drugmakers in particular rose above their peers and others in terms of pay. Novartis, GSK, AstraZeneca and Genentech made the list of the top-10 companies overall where employees are most satisfied with ...
Important Note: Recently, Beijing Shenzhou Cell Biotechnology Group Co. (hereinafter referred to as the “Company”) has received a Notice of Approval of Drug Clinical Trial from the State Drug Administration (hereinafter referred to as the “SDA”), agreeing that the Company’s self-developed product, SCTC21C Injection, can be used for the treatment of CD38+. (the “Company”) received a Notice of Approval for Clinical Trial of Drugs from the State Drug Administration (the “SDA”), agreeing to carry out clinical trials for the treatment of CD38+ hematologic malignancies for the Company’s self-developed product SCTC21C Injection. As there are many unpredictable factors in the process of clinical trials of pharmaceutical products, the results and timing of clinical trials, review and approval are subject to certain uncertainties, investors are advised to make decisions with caution and take precautions against investment risks. The relevant information is announced as follows: I. Basic Product Information 1. Product name: SCTC21C ...
Three years after bringing Jaguar Gene Therapy out of stealth, Deerfield Management is leading the funding of a manufacturing spinout from the Illinois company. Deerfield, with the help of ARCH Venture Partners and Nolan Capital, is backing a new company—Advanced Medicine Partners—which was formerly responsible for Jaguar’s chemistry, manufacturing and controls (CMC). The new firm seeks to provide best-in-class development of advanced medicines, including gene and cell therapies, addressing quality and scaling issues that have hindered new treatments. The management and technical teams have directed the CMC work of several approved products, including three gene therapies. In a release, CEO Andrew Knudten touted the experience of Advanced Medicine Partners’ genetic medicines team, which has manufactured roughly 350 non-GMP batches and supplied more than 20 preclinical studies. “With so many biotechnology companies being slowed or halted due to manufacturing challenges including product quality and scalability, we have the experienced people and ...
On January 11, Fosun Kate and Chenshi Health, a health management and comprehensive patient service platform under Sinopharm Holdings, jointly launched the first lymphoma pay-per-therapeutic value plan for Ekeda in China. Eligible patients who fail to achieve complete remission (CR) after treatment with Ekeda, a CAR-T treatment that originally cost $1.2 million, will receive a rebate of up to RMB600,000. The program will be China’s first innovative payment model for lymphoma drugs paid by the value of efficacy, and Ekeda will be China’s first bioinnovative drug paid by the value of efficacy. “If the complete remission indicator is not reached at three months, even if there is efficacy but the efficacy is not as good as complete remission, half of their out-of-pocket drug purchase price will still be refunded under the program. If this patient’s medication is completely self-funded, then the maximum return is 600,000 RMB for the medication. If ...
The 42nd Annual J.P. Morgan Healthcare Conference (hereinafter referred to as “JPM Conference”) was held on January 8-11, 2024 in San Francisco, California, USA. The conference invited “big names” from the pharmaceutical industry and the international investment and financing community to discuss cutting-edge advances in the industry and new trends for future development. Three companies incubated by Rehabilitation Capital’s New Drug Innovation Fund, namely, StarMed Unigene, StarNucleus Disease, and StarOptoVision, attended the JPM conference and delivered speeches in the biotechnology session, which gained great response. The company deeply participated in the international exchange of global biopharmaceuticals, laying the foundation for future innovation cooperation and exploring sustainable cooperation opportunities. JPM Conference has been held for 41 years since 1983, is the largest and most informative healthcare investment seminar in the global biomedical health field, which connects nearly 10,000 industry leaders, representatives of innovative enterprises, technology developers and investors worldwide, and is ...
Recently, according to the public information on the NMPA official website, the KL003 cell injection independently developed by Kanglin Biotechnology (Hangzhou) Co., Ltd. successfully obtained the NMPA’s implicit clinical trial license, with the acceptance number CXSL2300699, and is clinically used to treat transfusion-dependent beta in adults or children. -Thalassemia. The microspectrum biosafety service platform provides cell bank testing and strain library testing services for this product. β-thalassemia is a hemolytic anemia caused by defects or mutations in the β-globin gene (Hemoglobin β, HBB) on chromosome 11, resulting in partial or complete loss of β-globin-related functions, which brings great consequences to the patient’s life and health. The patients is more common in children and adolescents. Traditional treatments for thalassemia (blood transfusion, hematopoietic stem cell transplantation, etc.) are accompanied by side effects that cannot be ignored. The vast majority of patients lack the opportunity for radical cure, and there are obvious unmet ...
SHANGHAI, Jan. 07, 2024 /PRNewswire/ — Shanghai Argo Biopharmaceutical Co., Ltd. (“Argo”), a biotechnology company focused on the discovery and development of next-generation RNAi therapeutics, today announced that it has entered into two exclusive license and collaboration agreements with Novartis PHARMA AG (“Novartis”). Under the first agreement, Argo has granted Novartis exclusive global licenses to develop and commercialize a Phase 1 stage program. The first agreement also includes a research collaboration and Novartis also receives an option to potentially license compounds directed against up to two additional targets for cardiovascular disease treatment. Under the second agreement, Argo granted Novartis an exclusive ex-Greater China license to develop and commercialize a Phase 1/2a clinical-stage program for cardiovascular disease treatment. Discovered and developed with Argo’s cutting-edge RNAi platform technology, these clinical-stage assets offer industry-leading efficacy and durability therapies. The transactions have a combined potential value of up to $4.165 billion for Argo and ...
BridGene Biosciences, Inc., a leader in the discovery of small molecule drugs for traditional “hard-to-drug” targets, announced a strategic collaboration and licensing agreement with Galapagos NV. Under the collaboration, BridGene will use its chemoproteomics platform, IMTAC, to discover novel small molecule drug candidates against the collaboration targets. The parties will collaborate to advance the molecules to clinical candidates, which Galapagos has the exclusive rights to develop and commercialize. The preclinical research collaboration will focus on oncology targets named by Galapagos. Galapagos will pay BridGene up to $27 million in upfront and preclinical research milestone payments and more than $700 million in clinical and commercial milestones, assuming success of the programs. BridGene is also eligible to receive tiered royalties on net sales of each product resulting from the collaboration. “BridGene’s proven expertise in discovering small molecule drugs for challenging targets positions them as an ideal partner in pioneering new avenues in ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.